Peptide and small molecule agonists of EphA and their uses

1. A method of treating cancer in an individual, comprising administering to the individual a therapeutically effective amount of doxazosin, wherein the cancer is selected from the group consisting of skin cancer, lung cancer, pancreatic cancer and melanomas.

2. A method of treating cancer in an individual, comprising administering to the individual a therapeutically effective amount of an agonist of EphA receptor protein, the agonist inhibiting proliferation of cancer cells, the EphA receptor protein comprising at least one of EphA1, EphA2, or EphA3, the agonist having the general formula:

wherein

R 1 is selected from H, C 1-6 alkyl, C 1-6 aralkyl, C 1-6 alkanoyl, aryl, heterocyclyl, C 1-6 heterocyclylalkyl, C 1-6 carbocyclylalkyl, and carbocyclyl, or two occurrences of R 1 together are C 1-6 alkyl, thereby forming a ring;

R 2 , R 3 , and R 4 are independently selected from H, C 1-6 alkyl, C 1-6 aralkyl, C 1-6 heterocyclylalkyl, and C 1-6 carbocyclylalkyl;

R 5 is selected from C 1-6 alkyl, C 1-6 alkoxy, halogen, C 1-6 alkanoyl, C 1-6 alkoxycarbonyl, C(O)N(R 6 )(R 7 ), and SO 2 N(R 6 )(R 7 );

R 6 and R 7 are independently selected from H and C 1-6 alkyl;

X is selected from CH 2 , NH, and O;

each Y is independently selected from CH and N;

m is an integer from 1 to 2;

n is an integer from 1 to 3; and

p is an integer from 0 to 3,

wherein the cancer is selected from the group consisting of skin cancer, lung cancer, pancreatic cancer, and melanomas.